Should Doctors and Patients Be Informed When High-Risk Pharmacy Compounded …

Should doctors and patients be informed when high-risk pharmacy compounded …

Filed under: inpatient drug treatment programs

There is inherent risk when a compounding pharmacy acts as a manufacturer using non-sterile drug powder. In most states, including Pennsylvania, compounding pharmacy sterile processes do not undergo intensive state inspection. Should these conditions …
Read more on Philadelphia Inquirer (blog)

Biocon eyes Rs 100 cr from psoriasis drug in next four years

Filed under: inpatient drug treatment programs

NEW DELHI: Biotechnology firm Biocon today said it plans to launch skin disease drug under the brand Alzumab in the country in the current year and aims to garner Rs 100 crore in sales in the next four years. "We expect it (Alzumab) to be a Rs … for …
Read more on Economic Times

Bayer Rises as BofAML Predicts New Drug Success: Frankfurt Mover

Filed under: inpatient drug treatment programs

Bayer made progress last year with blood thinner Xarelto, eye drug Eylea, lung treatment riociguat, colorectal cancer medicine Stivarga and prostate cancer drug Alpharadin. The company gave its peak annual sales forecast of 5.5 billion euros for the …
Read more on Bloomberg

Gaining from Weight Loss: Should You Invest in the Obesity Fight?

Filed under: inpatient drug treatment programs

The pharmaceuticals industry has seen its fair share of obesity cures come and go, but two companies in particular have made huge recent gains thanks to their obesity treatment pills. In November 2012, biotech company Vivus (VVUS) released its …
Read more on DailyFinance (press release)